From: Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
Study name | Primary/secondary endpoint(s) (weeks) | Mean HbA1c at baseline (%) | Mean HbA1c reduction from baseline (%) with tirzepatide 5/10/15 mg | Percentage of patients who met +HbA1c < 7.0%; #HbA1c ≤ 6.5% and *HbA1c < 5.7% with tirzepatide 5/10/15 mg | Mean body weight at baseline (kg) | Mean reduction in body weight from baseline (kg) with tirzepatide 5/10/15 mg | Percentage of patients who met a weight loss of a≥ 5%; b≥ 10%; and c≥ 15% with tirzepatide 5/10/15 mg |
---|---|---|---|---|---|---|---|
SURPASS-1 [38] | 40 | 7.94 | 1.87/1.89/2.07 | +87/92/88 #82/81/86 *34/31/52 | 85.9 | 7.0/7.8/9.5 | a67/78/77 b31/40 /47 c13/17/27 |
SURPASS-2 [39] | 40 | 8.28 | 2.01/2.24/2.30 | +82/86/86 #69/77/80 *27/40/46 | 93.7 | 7.6/9.3/11.2 | a65/76/80 b34/47/57 c15/24/36 |
SURPASS-3 [40] | 52 | 8.17 | 1.93/2.20/2.37 | +82/90/93 #71/80/85 *26/39/48 | 94.3 | 7.5/10.7/12.9 | a66/84/88 b37/56/69 c13/28/43 |
SURPASS-4 [41] | 52 | 8.52 | 2.24/2.43/2.58 | +81/88/91 #66/76/81 *23/33/43 | 90.3 | 7.1/9.5/11.7 | a63/78/85 b36/53/66 c14/24/37 |
SURPASS-5 [42] | 40 | 8.31 | 2.11/2.40/2.34 | +87/90/85 #74/86/80 *24/42/50 | 95.2 | 5.4/7.5/8.8 | a56/68/85 b24/49/48 c8/28/27 |